Centanafadine

Last updated

Centanafadine
Centanafadine.svg
Legal status
Legal status
Identifiers
  • (1R,5S)-1-naphthalen-2-yl-3-azabicyclo[3.1.0]hexane
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
Formula C15H15N
Molar mass 209.292 g·mol−1
3D model (JSmol)
  • C1=C(C=CC2=CC=CC=C12)[C@@]34C[C@@H]3CNC4
  • InChI=1S/C15H15N/c1-2-4-12-7-13(6-5-11(12)3-1)15-8-14(15)9-16-10-15/h1-7,14,16H,8-10H2/t14-,15+/m1/s1
  • Key:HKHCSWPSUSWGLI-CABCVRRESA-N

Centanafadine (INN; former developmental code name EB-1020) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that began its development with Euthymics Bioscience after they acquired DOV Pharmaceutical. It was developed as a treatment for attention-deficit hyperactivity disorder (ADHD) and inhibits the reuptake of norepinephrine, dopamine, and serotonin with an IC50 ratio of 1:6:14, respectively. [1] [2] [3] [4] In 2011, Euthymics Bioscience spun off its development of centanafadine to a new company called Neurovance. [5] [6] In March 2017, Otsuka Pharmaceutical acquired Neurovance and the rights to centanafadine. [7] As of January 2018, Otsuka's pipeline indicates it is in Phase II and III clinical trials for a number of different applications to medical conditions. [8] [9] [10]

Contents

Pharmacology [1]
SiteIC50 (nM)ActionRef
SERT Tooltip Serotonin transporter83 nMAntagonist [1]
NET Tooltip Norepinephrine transporter6 nMAntagonist [1]
DAT Tooltip Dopamine transporter38 nMAntagonist [1]

See also

References

  1. 1 2 3 4 5 "Neurovance's EB-1020 SR for Adult ADHD Shows Stimulant-Like Efficacy and Good Tolerability in Phase 2a Trial" (PDF). Neurovance. Retrieved 14 January 2018.
  2. ↑ "3-Neurotransmitters, 1-Molecule: Optimized Ratios". Neurovance.
  3. ↑ "EB-1020, a Non-Stimulant Norepinephrine and Dopamine - Preferring Reuptake Inhibitor for the Treatment of Adult ADHD" (PDF). Neurovance. Archived from the original (PDF) on 2015-11-17. Retrieved 2015-11-14.
  4. ↑ Bymaster FP, Golembiowska K, Kowalska M, Choi YK, Tarazi FI (June 2012). "Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: implications for treatment of attention-deficit hyperactivity disorder". Synapse. 66 (6): 522–32. doi:10.1002/syn.21538. PMID   22298359. S2CID   38850652.
  5. ↑ "Euthymics". Ethismos Research Inc. Retrieved 14 January 2018.
  6. ↑ "EUTHYMICS BIOSCIENCE, INC. PRESENTS DATA THAT SUPPORT ADVANCING EB-1020 INTO CLINICAL TRIALS FOR ADULT ADHD" (PDF). Neurovance. December 7, 2011. Retrieved 14 January 2018.
  7. ↑ "Otsuka Pharmaceutical to Acquire Neurovance, Inc". Otsuka. Retrieved 14 January 2018.
  8. ↑ "Otsuka U.S. Research & Development Programs". Otsuka U.S. Otsuka. Retrieved 14 January 2018.[ permanent dead link ]
  9. ↑ Otsuka Pharmaceutical Development & Commercialization, Inc. (2021-09-17). "A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group Trial Evaluating the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder".
  10. ↑ Gunduz-Bruce H (2018-09-26). "SAGE-217 in major depressive disorder: a multicenter, randomized, double-blind, Phase 2 placebo-controlled trial". doi:10.26226/morressier.5b68175eb56e9b005965c44b. S2CID   266120058 . Retrieved 2023-06-26.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.